RU2006107925A - Рекомбинантные молекулы лубрицина и их использование - Google Patents
Рекомбинантные молекулы лубрицина и их использование Download PDFInfo
- Publication number
- RU2006107925A RU2006107925A RU2006107925/13A RU2006107925A RU2006107925A RU 2006107925 A RU2006107925 A RU 2006107925A RU 2006107925/13 A RU2006107925/13 A RU 2006107925/13A RU 2006107925 A RU2006107925 A RU 2006107925A RU 2006107925 A RU2006107925 A RU 2006107925A
- Authority
- RU
- Russia
- Prior art keywords
- protein
- polynucleotide
- seq
- individual
- nucleic acid
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/18—Growth factors; Growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/475—Growth factors; Growth regulators
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Organic Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Toxicology (AREA)
- Physical Education & Sports Medicine (AREA)
- Marine Sciences & Fisheries (AREA)
- Pain & Pain Management (AREA)
- Neurology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Biomedical Technology (AREA)
- Rheumatology (AREA)
- Cardiology (AREA)
- Neurosurgery (AREA)
- Heart & Thoracic Surgery (AREA)
- Pulmonology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Claims (32)
1. Выделенный белок, содержащий последовательность SEQ ID NO:9, 13, 17, 21 или 25.
2. Выделенный белок, содержащий последовательность SEQ ID NO:26, присоединенную к последовательности N-2 повтора(ов) SEQ ID NO:27, где N равно целому числу от 3 до 200.
3. Белок по п.2, где N равно целому числу от 5 до 50.
4. Белок по п.2, где N равно целому числу от 10 до 30.
5. Выделенный белок, содержащий последовательность SEQ ID NO:26 плюс SEQ ID NO:28 плюс [(N-2) повтор(ы) SEQ ID NO:27] плюс SEQ ID NO:29, где N равно целому числу от 10 до 30.
6. Выделенный полинуклеотид, содержащий последовательность нуклеиновой кислоты, кодирующую белок по п.1.
7. Выделенный полинуклеотид, содержащий последовательность нуклеиновой кислоты, кодирующую белок по п.2.
8. Выделенный полинуклеотид, содержащий последовательность нуклеиновой кислоты, кодирующую белок по п.3.
9. Выделенный полинуклеотид, содержащий последовательность нуклеиновой кислоты, кодирующую белок по п.4.
10. Выделенный полинуклеотид, содержащий последовательность нуклеиновой кислоты, кодирующую белок по п.5.
11. Выделенный белок, содержащий последовательность SEQ ID NO:7, 11, 15, 19 или 23.
12. Выделенный полинуклеотид, содержащий последовательность нуклеиновой кислоты, кодирующую белок по п.11.
13. Полинуклеотид по п.6, где указанный полинуклеотид содержит SEQ ID NO:8, 12, 16, 20 или 24.
14. Полинуклеотид по п.12, где указанный полинуклеотид содержит последовательность SEQ ID NO:6, 10, 14, 18 или 22.
15. Выделенный полинуклеотид, содержащий полинуклеотид, который, по всей своей длине по крайней мере на 80% идентичен последовательности SEQ ID NO:6, 10, 14, 18 или 22.
16. Полинуклеотид по п.15, содержащий полинуклеотид, который, который имеет по крайней мере 90%-ную идентичность.
17. Полинуклеотид по п.15, содержащий полинуклеотид, который имеет по крайней мере 95%-ную идентичность.
18. Полинуклеотид по п.15, содержащий полинуклеотид, который имеет по крайней мере 99%-ную идентичность.
19. Белок по п.1 или 2, где указанный белок связан О-связью с β-(1-3)-Gal-GalNac.
20. Композиция, содержащая терапевтически эффективное количество белка по п.19 в фармацевтически приемлемом носителе.
21. Композиция по п.20, дополнительно содержащая гиалуронан или гилан.
22. Способ лечения индивидуума, предусматривающий получение композиции по п.20 и, введение указанной композиции в ткань указанного индивидуума.
23. Способ по п.22, где указанная ткань выбрана из группы, включающий хрящ, синовиальную оболочку, мениск, сухожилие, брюшину, перикард и плевру.
24. Способ по п.23, где указанной тканью является хрящ.
25. Способ по п.22, дополнительно предусматривающий стадию, выбранную из группы, включающей: введение индивидууму анестетика; введение индивидууму противовоспалительного лекарственного средства; введение индивидууму антибиотика; отсасывание у индивидуума жидкости; промывку ткани индивидуума и визуализации этой ткани.
26. Способ по п.22, где индивидуум выбран из группы, включающий мышь, крысу, кошку, собаку, лошадь и человека.
27. Способ по п.26, где указанным индивидуумом является человек.
28. Экспрессионный вектор, содержащий полинуклеотид по п.6 или 7, операбельно связанный с последовательностью, регулирующей экспрессию.
29. Способ получения рекомбинантного белка, предусматривающий культивирование клеток, трансформированных экспрессионным вектором по п.28, в жидкой культуральной среде, и выделение рекомбинантного белка из указанной среды.
30. Способ по п.29, где указанное выделение белка предусматривает концентрирование белка путем фильтрации среды через мембрану; сбор оставшегося белка из указанной мембраны, и солюбилизацию собранного белка в забуференном солевом растворе, содержащем гидрохлорид L-аргинина в концентрации от 0,1 до 2,0 М.
31. Способ по п.30, где концентрация гидрохлорида L-аргинина составляет 0,5М.
32. Выделенное антитело, специфичное в отношении белка по п.1 или 2.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US49574103P | 2003-08-14 | 2003-08-14 | |
| US60/495,741 | 2003-08-14 |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2009130434/10A Division RU2009130434A (ru) | 2003-08-14 | 2009-08-07 | Рекомбинантные молекулы лубрицина и их использование |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| RU2006107925A true RU2006107925A (ru) | 2006-07-27 |
| RU2376313C2 RU2376313C2 (ru) | 2009-12-20 |
Family
ID=34193342
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2006107925/13A RU2376313C2 (ru) | 2003-08-14 | 2004-08-13 | Рекомбинантные молекулы лубрицина и их использование |
| RU2009130434/10A RU2009130434A (ru) | 2003-08-14 | 2009-08-07 | Рекомбинантные молекулы лубрицина и их использование |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2009130434/10A RU2009130434A (ru) | 2003-08-14 | 2009-08-07 | Рекомбинантные молекулы лубрицина и их использование |
Country Status (21)
| Country | Link |
|---|---|
| US (6) | US7642236B2 (ru) |
| EP (1) | EP1663291B1 (ru) |
| JP (1) | JP2007502122A (ru) |
| KR (1) | KR101078202B1 (ru) |
| CN (2) | CN1867350A (ru) |
| AU (2) | AU2004264970B2 (ru) |
| BR (1) | BRPI0413553A (ru) |
| CR (1) | CR8204A (ru) |
| DK (1) | DK1663291T3 (ru) |
| EC (1) | ECSP066364A (ru) |
| ES (1) | ES2388970T3 (ru) |
| HK (1) | HK1089110A1 (ru) |
| IL (2) | IL173258A (ru) |
| MX (1) | MXPA06001658A (ru) |
| NO (1) | NO20060475L (ru) |
| NZ (1) | NZ545021A (ru) |
| RU (2) | RU2376313C2 (ru) |
| SG (1) | SG145724A1 (ru) |
| UA (1) | UA91818C2 (ru) |
| WO (1) | WO2005016130A2 (ru) |
| ZA (1) | ZA200601291B (ru) |
Families Citing this family (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6743774B1 (en) * | 1999-04-23 | 2004-06-01 | Rhode Island Hospital | Tribonectins |
| CA2575086A1 (en) * | 2004-07-23 | 2006-02-02 | Mucosal Therapeutics Llc | Compositions and methods for viscosupplementation |
| US20090068247A1 (en) * | 2007-09-12 | 2009-03-12 | Mucosal Therapeutics | Biocompatible devices coated with a tribonectin and methods for their production |
| US20090104148A1 (en) * | 2007-09-18 | 2009-04-23 | Jay Gregory D | Treatment and prevention of joint disease |
| US8506944B2 (en) | 2008-05-07 | 2013-08-13 | The Regents Of The University Of California | Replenishment and enrichment of ocular surface lubrication |
| CA2722913C (en) * | 2008-05-07 | 2018-02-27 | Schepens Eye Research Institute | Prg4 compositions and methods for therapeutic treatment of dry eye |
| ES2534082T3 (es) * | 2009-01-13 | 2015-04-17 | Lubris Llc | Modulación terapéutica de la lubricación del límite del epitelio vaginal |
| WO2010135736A2 (en) * | 2009-05-22 | 2010-11-25 | Singularis Inc. | Application and uses of prg4 and therapeutic modulation thereof |
| WO2011091000A2 (en) * | 2010-01-19 | 2011-07-28 | Singularis, Inc. | Oral care compositions and methods |
| US8716204B2 (en) | 2010-07-27 | 2014-05-06 | Zimmer, Inc. | Synthetic synovial fluid compositions and methods for making the same |
| US20130116186A1 (en) * | 2011-10-04 | 2013-05-09 | Rhode Island Hospital, A Lifespan Partner | Lubricin injections to maintain cartilage health |
| US20150361452A1 (en) * | 2013-01-25 | 2015-12-17 | Baylor College Of Medicine | A Helper-Dependent Adenoviral Gene Therapy Delivery and Expression System |
| US20150010606A1 (en) * | 2013-07-08 | 2015-01-08 | Arthrex, Inc. | Intra-articular injection and implant attachment of molecule consisting of lubricin and extracellular superoxide dismutase or hyaluronic acid and extracellular superoxide dismutase |
| WO2015057993A1 (en) * | 2013-10-16 | 2015-04-23 | Ensisheim Partners Llc | Protein-specific formulations |
| US9982027B2 (en) * | 2013-10-22 | 2018-05-29 | Lubris Llc | Control of rheological properties of mixed hyaluronate/lubricin solutions |
| JP6571101B2 (ja) | 2013-11-26 | 2019-09-04 | ルブリス，エルエルシー． | 細胞間相互作用を阻害するための組成物及び方法 |
| AU2016211694B2 (en) * | 2015-01-26 | 2021-11-11 | Lubris Llc | Use of PRG4 as an anti-inflammatory agent |
| HUE051774T2 (hu) | 2016-01-13 | 2021-03-29 | Genzyme Corp | Oszteoprotektív géneket, például HAS2-t és lubricint expresszáló rekombináns AAV vektorok, amelyek alkalmazhatók emlõsben oszteoartritisz és azzal kapcsolatos ízületi állapotok kezelésében |
| JP6937309B2 (ja) | 2016-01-27 | 2021-09-22 | ジャスト−エヴォテック バイオロジックス、インコーポレイテッド | ハイブリッドプロモーターおよびその使用 |
| MX2020013869A (es) * | 2018-06-21 | 2021-03-02 | Lubris Llc | Lubricina para uso en curacion de heridas referencia cruzada con solicitudes relacionadas. |
| CN113573724A (zh) * | 2019-01-15 | 2021-10-29 | 康奈尔大学 | 重组润滑素和组合物以及其使用方法 |
| AU2021227771A1 (en) * | 2020-02-24 | 2022-10-06 | Novartis Ag | Purification of recombinantly produced polypeptides |
| IT202000022636A1 (it) | 2020-09-25 | 2022-03-25 | Ente Ospedaliero Specializzato In Gastroenterologia Istituto Nazionale Di Ricovero E Cura A Caratter | “terapia di combinazione di sorafenib e/o regorafenib con la proteina ricombinante umana proteoglicano-4 per il trattamento dell'epatocarcinoma” |
Family Cites Families (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US2734862A (en) * | 1956-02-14 | Synthetic casein fiber elastic grease | ||
| US2487377A (en) * | 1948-04-17 | 1949-11-08 | Socony Vacuum Oil Co Inc | Lubricant |
| US2878184A (en) * | 1953-12-29 | 1959-03-17 | Rockwell Mfg Co | Hydrocarbon resistant glycerol base lubricant |
| AR207237A1 (es) * | 1974-02-25 | 1976-09-22 | Thomas A | Procedimiento para obtener extractos biologicos estables liofilizados solubles constituidos por complejos proteicos termorresistentes |
| EP0050644B1 (en) * | 1980-04-25 | 1985-09-18 | A/S Orthana Kemisk Fabrik | Sterilized, preserved, stable mucine-containing solutions and sterilization method |
| US5403592A (en) * | 1987-08-25 | 1995-04-04 | Macnaught Pty Limited | Lubricant composition for rheumatism |
| GB8803697D0 (en) * | 1988-02-17 | 1988-03-16 | Deltanine Research Ltd | Clinical developments using amniotic membrane cells |
| US5510418A (en) * | 1988-11-21 | 1996-04-23 | Collagen Corporation | Glycosaminoglycan-synthetic polymer conjugates |
| US5260417A (en) * | 1989-04-03 | 1993-11-09 | Genetics Institute, Inc. | Megakaryocyte growth promoting activity protein |
| US6433142B1 (en) | 1989-08-08 | 2002-08-13 | Genetics Institute, Llc | Megakaryocyte stimulating factors |
| US5326558A (en) * | 1989-08-08 | 1994-07-05 | Genetics Institute, Inc. | Megakaryocytopoietic factor |
| AU652022B2 (en) * | 1991-02-12 | 1994-08-11 | C.R. Bard Inc. | Injectable medical device |
| US5605938A (en) * | 1991-05-31 | 1997-02-25 | Gliatech, Inc. | Methods and compositions for inhibition of cell invasion and fibrosis using dextran sulfate |
| CN1107891A (zh) * | 1994-03-04 | 1995-09-06 | 上海贝特生物技术有限公司 | 人促巨核细胞生成素及其分离纯化和基因克隆方法及应用 |
| US5515590A (en) * | 1994-07-19 | 1996-05-14 | University Of Kentucky Research Foundation | Method for reducing the generation of wear particulates from an implant |
| US5709020A (en) * | 1994-07-19 | 1998-01-20 | University Of Kentucky Research Foundation | Method for reducing the generation of wear particulates from an implant |
| US5510122A (en) * | 1994-09-28 | 1996-04-23 | The Research Foundation Of State University Of New York | Preparation and use of whole saliva |
| US7001881B1 (en) * | 1999-04-23 | 2006-02-21 | Rhode Island Hospital | Tribonectins |
| US6960562B2 (en) * | 1999-04-23 | 2005-11-01 | Rhode Island Hospital, A Lifespan Partner | Tribonectin polypeptides and uses thereof |
| US6743774B1 (en) | 1999-04-23 | 2004-06-01 | Rhode Island Hospital | Tribonectins |
| WO2001007068A1 (en) * | 1999-07-23 | 2001-02-01 | Case Western Reserve University | Novel methods and reagents for the treatment of osteoarthritis |
| US20030180948A1 (en) * | 2000-12-29 | 2003-09-25 | Hutchins Jeff T. | Superficial zone protein and methods of making and using same |
| EP1440981A3 (en) * | 2003-01-21 | 2005-11-23 | Research Association for Biotechnology | Full-length human cdna |
-
2004
- 2004-08-13 NZ NZ545021A patent/NZ545021A/en not_active IP Right Cessation
- 2004-08-13 UA UAA200602706A patent/UA91818C2/ru unknown
- 2004-08-13 SG SG200805896-8A patent/SG145724A1/en unknown
- 2004-08-13 CN CNA2004800299041A patent/CN1867350A/zh active Pending
- 2004-08-13 CN CN2012104146501A patent/CN102924584A/zh active Pending
- 2004-08-13 KR KR1020067003110A patent/KR101078202B1/ko not_active IP Right Cessation
- 2004-08-13 RU RU2006107925/13A patent/RU2376313C2/ru not_active IP Right Cessation
- 2004-08-13 EP EP04781229A patent/EP1663291B1/en active Active
- 2004-08-13 WO PCT/US2004/026508 patent/WO2005016130A2/en active Application Filing
- 2004-08-13 DK DK04781229.2T patent/DK1663291T3/da active
- 2004-08-13 AU AU2004264970A patent/AU2004264970B2/en not_active Ceased
- 2004-08-13 JP JP2006523436A patent/JP2007502122A/ja active Pending
- 2004-08-13 BR BRPI0413553-9A patent/BRPI0413553A/pt not_active IP Right Cessation
- 2004-08-13 MX MXPA06001658A patent/MXPA06001658A/es active IP Right Grant
- 2004-08-13 US US10/567,764 patent/US7642236B2/en not_active Expired - Fee Related
- 2004-08-13 ES ES04781229T patent/ES2388970T3/es active Active
-
2006
- 2006-01-19 IL IL173258A patent/IL173258A/en not_active IP Right Cessation
- 2006-01-19 CR CR8204A patent/CR8204A/es unknown
- 2006-01-30 NO NO20060475A patent/NO20060475L/no not_active Application Discontinuation
- 2006-02-13 ZA ZA200601291A patent/ZA200601291B/xx unknown
- 2006-02-14 EC EC2006006364A patent/ECSP066364A/es unknown
- 2006-10-10 HK HK06111118.8A patent/HK1089110A1/xx unknown
-
2009
- 2009-06-24 IL IL199528A patent/IL199528A/en not_active IP Right Cessation
- 2009-08-07 RU RU2009130434/10A patent/RU2009130434A/ru not_active Application Discontinuation
- 2009-11-19 US US12/622,141 patent/US7893029B2/en not_active Expired - Fee Related
- 2009-11-23 US US12/624,112 patent/US7897571B2/en not_active Expired - Fee Related
-
2010
- 2010-04-16 AU AU2010201537A patent/AU2010201537B2/en not_active Ceased
-
2011
- 2011-02-25 US US13/035,529 patent/US8420793B2/en not_active Expired - Fee Related
-
2013
- 2013-03-08 US US13/791,346 patent/US8987205B2/en not_active Expired - Fee Related
-
2015
- 2015-02-05 US US14/614,809 patent/US20150343019A1/en not_active Abandoned
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2006107925A (ru) | Рекомбинантные молекулы лубрицина и их использование | |
| Sorokin et al. | Development of tubular and glomerular cells of the kidney | |
| EP0174993A1 (en) | Bone protein purification process | |
| Frederickson et al. | The fine structure of perinotochordal microfibrils in control and enzyme‐treated chick embryos | |
| CN1070611C (zh) | 杂交瘤细胞系及其产生的抗人多能粒细胞集落刺激因子单克隆抗体 | |
| CN115960209A (zh) | 一种重组人源化胶原蛋白及其应用 | |
| CN104031135B (zh) | 树蛙防御肽PopuDef及其基因和应用 | |
| DE2749023A1 (de) | Zellkulturverfahren fuer saeugetierzellen zur produktion von wirkstoffen | |
| CN103074303A (zh) | 产生抗人ngal特异性单克隆抗体的杂交瘤细胞株及其产生的单克隆抗体与应用 | |
| CN1284797C (zh) | 人重组组织因子的构建表达、纯化方法及其应用 | |
| CN107501562A (zh) | 一种质子化吗啡啉修饰的含磷树状大分子及其制备和应用 | |
| Peterson et al. | Comparison of in vitro monoclonal antibody production methods with an in vivo ascites production technique | |
| CN1920571A (zh) | 畜禽疫病、药物残留自身红细胞凝集快速检测法 | |
| CN106754647B (zh) | 一种大鲵皮肤表皮细胞的分离、培养及鉴定方法 | |
| CN104447977A (zh) | 一种重组人骨形态发生蛋白-2的纯化生产方法 | |
| CN101353668A (zh) | 鼠β-防御素1的重组质粒、多肽及其用途与制备方法 | |
| CN104480064A (zh) | 眼镜蛇毒神经生长因子诱导干细胞成软骨分化的方法 | |
| CN114031672A (zh) | 一种多肽及其在制备软骨修复和/或骨关节炎药物中的应用 | |
| CN1053698C (zh) | 细胞培养生产促红细胞生成素的方法 | |
| CN1059237C (zh) | 重组人肝细胞生成素的生产方法及其治疗严重肝病的用途 | |
| CN101481692A (zh) | 无血清制备重组人类凝血因子ix | |
| CN1321690A (zh) | 一种新型双功能水蛭素及其制备方法和应用 | |
| CN109022442A (zh) | 一种可有效抑制骨肉瘤生长的生物重组型miR124-3p | |
| CN113234745B (zh) | 利用PTD-Tat实现海洋微生物低温脂肪酶基因的跨膜转导方法 | |
| CN114916501B (zh) | 二亚苯基碘鎓氯化物用于类风湿关节炎模型造模的用途、类风湿关节炎模型造模方法 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MM4A | The patent is invalid due to non-payment of fees |
Effective date: 20130814 |